

Anti-IL-12 β (Ustekinumab), Human IgG1 Antibody

rev 02/21

CATALOG NO.: A2137-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a human IgG1 κ monoclonal antibody that was generated using human immunoglobulin (hu-Ig) transgenic mice. This monoclonal antibody specifically binds to the p40 subunit of IL-12 and IL-23, thus preventing their association with the IL-12R β 1 receptor expressed on the NK cell and T cell surface and resulting in reduced IL-12 and IL-23 mediated signaling, activation, and cytokine production. The original monoclonal antibody was developed by Centocor and received FDA approval in 2009 for use in the treatment of psoriasis. Recently, it has been approved for the treatment of Crohn's disease and ulcerative colitis.

ALTERNATE NAMES: IL-12 β , IL12 β , IL 12 β

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Ustekinumab

MOLECULAR WEIGHT: 148 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

APPLICATIONS AND USAGE: In vitro studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-6R α (Sarilumab), Human IgG1 Antibody (A2133)
 Anti-TNF- α (Adalimumab), humanized Antibody (A1048)
 Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)
 Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (A1098)
 Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody (A1099)

FOR RESEARCH USE ONLY! Not to be used on humans.